Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 14/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454119 | 0.80 | MAPT (0.46) | CYP11B1GPR84POLBMAPTNPSR1 | |
| SCHEMBL3717538 | 0.75 | CA12 (0.43) | POLBMAPTNPSR1RAB9ACA12 | |
| SCHEMBL27848151 | 0.74 | CYP11B1 (0.51) | CYP11B1GPR84POLBMAPTCYP11B2 | |
| SCHEMBL4508899 | 0.70 | CYP11B1 (1.00) | CYP11B1GPR84CYP11B2 | |
| SCHEMBL3454455 | 0.69 | THRA (0.43) | POLBMAPTNPSR1CA12CA1 | |
| SCHEMBL14100945 | 0.68 | MAPT (0.54) | CYP11B1POLBMAPTNPSR1CYP11B2 | |
| SCHEMBL13249061 | 0.66 | CYP11B1 (0.68) | CYP11B1GPR84CYP11B2 | |
| SCHEMBL4789958 | 0.66 | CTNNB1 (0.47) | — | |
| Diphenylether SCHEMBL29220492 | 0.66 | CYP2A6 (0.65) | CYP11B1POLBMAPTNPSR1CYP11B2 | |
| SCHEMBL12887013 | 0.65 | TNF (0.44) | CYP11B1GPR84POLBMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816382-B2 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | P2RY1, P2RY11, UTS2R | CYP11B1 1303/4885GPR84 149/4885POLB 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.